Protocol: STUDY00007474

A randomized double-blind study to evaluate the efficacy, safety and tolerability of AZD2693 in participants with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis who are carriers of the PNPLA3 rs738409 148M risk Allele

The University at Buffalo (UB) Department of Medicine is recruiting adults with non-alcoholic steatohepatitis (or NASH) for a year-long clinical trial. NASH is a form of liver disease that is caused by too much fat in the liver. The goal of the study is to learn more about the safety and effectiveness of an injectable drug that may help to treat NASH by lowering the levels of fat in the liver.

Participants will be enrolled in this study for about 1 year. They will either receive the study drug or a placebo, which looks like the study drug but has no active medication. Both the study drug and the placebo will be injected into the skin once per month during study visits. Participants will be randomly assigned (which happens by chance, like flipping a coin) to one of 2 groups: (1) will receive the study drug or (2) will receive the placebo. They will complete 2 screening visits, 19 visits over one year during the treatment phase, and 3 follow-up visits. They will also complete physical exams, lab tests, imaging tests, 2 liver biopsies, and surveys. They will receive $75 for each completed study visit.

Compensation: No

Eligibility

Age Group: Adults

Principal Investigator: AJAY CHAUDHURI

ClinicalTrials.gov: Open Study

Contact(s)